February 11th, 2014
FDA Investigating Heart Failure Risk Linked to Saxagliptin
Larry Husten, PHD
The FDA said today that it is conducting an investigation of a possible increased risk for heart failure associated with the diabetes drug saxagliptin. Saxagliptin, a dipeptidyl peptidase 4 inhibitor, is marketed by AstraZeneca as Onglyza and Kombiglyze XR. (AstraZeneca recently completed the purchase of all rights to the drug from its manufacturer, Bristol Myers-Squibb.) The investigation stems […]
NEJM Journal Watch — Recent Cardiology Articles- Persistent Symptoms After Valve Replacement for Severe Aortic Stenosis
- Is Diltiazem Safe in Patients with AF Taking Apixaban or Rivaroxaban?
- Does Lowering High Childhood Lipid Levels Prevent Adverse Cardiovascular Events in Adulthood?
- Self-Expanding Supraannular Valve vs. Balloon-Expandable Valve in TAVR for Small Aortic Annulus
- A New TAVR Prosthesis for Aortic Regurgitation Shows Promise